Cargando…

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1

The spread of COVID-19 continues, expressed by periodic wave-like increases in morbidity and mortality. The reason for the periodic increases in morbidity is the emergence and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy of monoclonal antibodies (mAbs) has been reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Pochtovyi, Andrei A., Kustova, Daria D., Siniavin, Andrei E., Dolzhikova, Inna V., Shidlovskaya, Elena V., Shpakova, Olga G., Vasilchenko, Lyudmila A., Glavatskaya, Arina A., Kuznetsova, Nadezhda A., Iliukhina, Anna A., Shelkov, Artem Y., Grinkevich, Olesia M., Komarov, Andrei G., Logunov, Denis Y., Gushchin, Vladimir A., Gintsburg, Alexander L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611309/
https://www.ncbi.nlm.nih.gov/pubmed/37896937
http://dx.doi.org/10.3390/vaccines11101533
_version_ 1785128461037207552
author Pochtovyi, Andrei A.
Kustova, Daria D.
Siniavin, Andrei E.
Dolzhikova, Inna V.
Shidlovskaya, Elena V.
Shpakova, Olga G.
Vasilchenko, Lyudmila A.
Glavatskaya, Arina A.
Kuznetsova, Nadezhda A.
Iliukhina, Anna A.
Shelkov, Artem Y.
Grinkevich, Olesia M.
Komarov, Andrei G.
Logunov, Denis Y.
Gushchin, Vladimir A.
Gintsburg, Alexander L.
author_facet Pochtovyi, Andrei A.
Kustova, Daria D.
Siniavin, Andrei E.
Dolzhikova, Inna V.
Shidlovskaya, Elena V.
Shpakova, Olga G.
Vasilchenko, Lyudmila A.
Glavatskaya, Arina A.
Kuznetsova, Nadezhda A.
Iliukhina, Anna A.
Shelkov, Artem Y.
Grinkevich, Olesia M.
Komarov, Andrei G.
Logunov, Denis Y.
Gushchin, Vladimir A.
Gintsburg, Alexander L.
author_sort Pochtovyi, Andrei A.
collection PubMed
description The spread of COVID-19 continues, expressed by periodic wave-like increases in morbidity and mortality. The reason for the periodic increases in morbidity is the emergence and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy of monoclonal antibodies (mAbs) has been reported, especially against Omicron subvariants. There have been reports of a decrease in the efficacy of specific antiviral drugs as a result of mutations in the genes of non-structural proteins. This indicates the urgent need for practical healthcare to constantly monitor pathogen variability and its effect on the efficacy of preventive and therapeutic drugs. As part of this study, we report the results of the continuous monitoring of COVID-19 in Moscow using genetic and virological methods. As a result of this monitoring, we determined the dominant genetic variants and identified the variants that are most widespread, not only in Moscow, but also in other countries. A collection of viruses from more than 500 SARS-CoV-2 isolates has been obtained and characterized. The genetic lines XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, representing the greatest concern, were identified among the dominant variants. We studied the in vitro efficacy of mAbs Tixagevimab + Cilgavimab (Evusheld), Sotrovimab, Regdanvimab, Casirivimab + Imdevimab (Ronapreve), and Bebtelovimab, as well as the specific antiviral drugs Remdesivir, Molnupiravir, and Nirmatrelvir, against these genetic lines. At the current stage of the COVID-19 pandemic, the use of mAbs developed against early SARS-CoV-2 variants has little prospect. Specific antiviral drugs retain their activity, but further monitoring is needed to assess the risk of their efficacy being reduced and adjust recommendations for their use.
format Online
Article
Text
id pubmed-10611309
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106113092023-10-28 In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1 Pochtovyi, Andrei A. Kustova, Daria D. Siniavin, Andrei E. Dolzhikova, Inna V. Shidlovskaya, Elena V. Shpakova, Olga G. Vasilchenko, Lyudmila A. Glavatskaya, Arina A. Kuznetsova, Nadezhda A. Iliukhina, Anna A. Shelkov, Artem Y. Grinkevich, Olesia M. Komarov, Andrei G. Logunov, Denis Y. Gushchin, Vladimir A. Gintsburg, Alexander L. Vaccines (Basel) Article The spread of COVID-19 continues, expressed by periodic wave-like increases in morbidity and mortality. The reason for the periodic increases in morbidity is the emergence and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy of monoclonal antibodies (mAbs) has been reported, especially against Omicron subvariants. There have been reports of a decrease in the efficacy of specific antiviral drugs as a result of mutations in the genes of non-structural proteins. This indicates the urgent need for practical healthcare to constantly monitor pathogen variability and its effect on the efficacy of preventive and therapeutic drugs. As part of this study, we report the results of the continuous monitoring of COVID-19 in Moscow using genetic and virological methods. As a result of this monitoring, we determined the dominant genetic variants and identified the variants that are most widespread, not only in Moscow, but also in other countries. A collection of viruses from more than 500 SARS-CoV-2 isolates has been obtained and characterized. The genetic lines XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, representing the greatest concern, were identified among the dominant variants. We studied the in vitro efficacy of mAbs Tixagevimab + Cilgavimab (Evusheld), Sotrovimab, Regdanvimab, Casirivimab + Imdevimab (Ronapreve), and Bebtelovimab, as well as the specific antiviral drugs Remdesivir, Molnupiravir, and Nirmatrelvir, against these genetic lines. At the current stage of the COVID-19 pandemic, the use of mAbs developed against early SARS-CoV-2 variants has little prospect. Specific antiviral drugs retain their activity, but further monitoring is needed to assess the risk of their efficacy being reduced and adjust recommendations for their use. MDPI 2023-09-28 /pmc/articles/PMC10611309/ /pubmed/37896937 http://dx.doi.org/10.3390/vaccines11101533 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pochtovyi, Andrei A.
Kustova, Daria D.
Siniavin, Andrei E.
Dolzhikova, Inna V.
Shidlovskaya, Elena V.
Shpakova, Olga G.
Vasilchenko, Lyudmila A.
Glavatskaya, Arina A.
Kuznetsova, Nadezhda A.
Iliukhina, Anna A.
Shelkov, Artem Y.
Grinkevich, Olesia M.
Komarov, Andrei G.
Logunov, Denis Y.
Gushchin, Vladimir A.
Gintsburg, Alexander L.
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title_full In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title_fullStr In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title_full_unstemmed In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title_short In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
title_sort in vitro efficacy of antivirals and monoclonal antibodies against sars-cov-2 omicron lineages xbb.1.9.1, xbb.1.9.3, xbb.1.5, xbb.1.16, xbb.2.4, bq.1.1.45, ch.1.1, and cl.1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611309/
https://www.ncbi.nlm.nih.gov/pubmed/37896937
http://dx.doi.org/10.3390/vaccines11101533
work_keys_str_mv AT pochtovyiandreia invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT kustovadariad invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT siniavinandreie invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT dolzhikovainnav invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT shidlovskayaelenav invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT shpakovaolgag invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT vasilchenkolyudmilaa invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT glavatskayaarinaa invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT kuznetsovanadezhdaa invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT iliukhinaannaa invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT shelkovartemy invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT grinkevicholesiam invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT komarovandreig invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT logunovdenisy invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT gushchinvladimira invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1
AT gintsburgalexanderl invitroefficacyofantiviralsandmonoclonalantibodiesagainstsarscov2omicronlineagesxbb191xbb193xbb15xbb116xbb24bq1145ch11andcl1